AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s Tagrisso has been recommended for approval in the EU for treating advanced, unresectable EGFR-mutated non-small cell lung cancer, after demonstrating significant efficacy in extending progression-free survival in the LAURA Phase III trial. The trial results indicate that Tagrisso can reduce the risk of disease progression or death by 84% compared to placebo, marking a promising development for patients and investors interested in the oncology market. With this recommendation, AstraZeneca strengthens its position in the treatment of lung cancer, potentially impacting its stock and market presence positively.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
